The Claim

In obese mice, the weight loss and metabolic benefits of G49 depend on the concurrent activation of both glucagon and GLP-1 receptors, as pharmacological blockade of either receptor reduces body weight loss by more than 60% and eliminates activation of brown adipose tissue and increased energy expenditure.

Source: The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
66score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In obese mice, a compound called G49 reduces weight and improves metabolism only when both glucagon and GLP-1 receptors are active; blocking either receptor significantly reduces weight loss and stops the activation of brown fat and the increase in energy use.

See the scientific wording

In obese mice, the weight loss and metabolic benefits of G49 require both glucagon and GLP-1 receptor activation, as blocking either receptor reduces body weight loss by more than 60% and abolishes brown fat activation and energy expenditure.

Why this might work

The drug turns on two special receptors in the body: one in fat tissue that makes it release fat into the blood, and another in the pancreas that helps release insulin. The released fat travels to the liver, which then produces a signal that tells brown fat to burn energy as heat. Both receptors must be active for this chain to work — if either one is blocked, the fat doesn't get released, the liver doesn't send the signal, and the brown fat doesn't burn energy, so weight loss stops.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

    G49 is a drug that turns on two special switches in the body (glucagon and GLP-1 receptors) to help obese mice burn fat and lose weight. The study shows both switches need to be on for it to work well — if one is turned off, the fat-burning effect likely stops.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.